Randomized, Controlled Trial of Extended-Release Niacin (Niaspan®) to Augment Subacute Ischemic Stroke Recovery
Phase II, Randomized, Double-Blinded, Placebo-Controlled Trial of Extended-Release Niacin (Niaspan®) to Augment Subacute Ischemic Stroke Recovery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with clinical ischemic stroke able to enroll between 72 hours and 7 days after symptom onset.
- Patients age 18-85, inclusive.
- NIHSS score of 4-21, inclusive, prior to treatment.
- Signed IRB-approved informed consent by patient or authorized representative.
Exclusion Criteria:
General
- Participation in another study with an investigational drug or device.
- Women known to be pregnant, lactating, or of childbearing potential with a positive urine beta-HCG.
- Patients using niacin within the 7 days previous to their stroke.
Safety Related
- Unstable angina.
- Acute Myocardial infarction.
- Concurrent arterial bleeding.
- Active peptic ulcer disease.
- Platelet count less than 100,000 per microliter.
- Internationally Normalized Ratio (INR) greater than 1.3 without use of warfarin.
- Concurrent use of bile acid sequestrants (colestipol and cholestyramine)
- Baseline systolic blood pressure less than 100 mmHg.
- History of significant hepatic dysfunction.
- Allergy or hypersensitivity to aspirin.
- Concurrent use of amiodarone, gemfibrozil, fibrate or other bile acid resin, cyclosporine, itraconazole, ketaconazole, telithromycin, erythromycin, clarithromycin, HIV protease inhibitors, nefazodone, danazol.
- Allergy or hypersensitivity to extended-release niacin.
- Allergy or hypersensitivity to statin agents.
Potentially Interfering with Outcomes Assessment
- Prior history of dementia.
- Patients without fixed address or those deemed unlikely to present for follow-up by the investigator.
- Patients whose life expectancy is less than 24 weeks.
- Pre-stroke modified Rankin score>2.
- Glucose less than 50 mg/dl.
- Other serious illness (e.g., severe hepatic, cardiac, or renal failure; or a complex disease that may confound treatment assessment).
Imaging Related
- Evidence of primary intra-parenchymal hemorrhage on initial neuroimaging study.
- Neuroimaging evidence of a nonvascular cause for the neurological symptoms.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
Placebo daily
|
Placebo tablet once daily
|
|
Experimental: Niaspan® 500mg
Extended-release niacin 500mg daily
|
500mg or 1000mg tablet once daily
Other Names:
|
|
Experimental: Niaspan® 1000mg
Extended-release niacin 1000mg daily
|
500mg or 1000mg tablet once daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Serious Adverse Events
Time Frame: 24 weeks
|
Analysis of the frequency and type of serious adverse events among patients in each study arm/group
|
24 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Functional Recovery
Time Frame: 24 weeks
|
Exploratory efficacy analysis of the differences in functional recovery between each study arm as measured using the National Institutes of Stroke Scale score.
The National Institutes of Health Stroke Scale score is a 15-item neurological examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss.
Ratings for each item are scored on a 3- to 5-point scale, with 0 as normal, and there is an allowance for untestable items.
Scores range from 0 to 42, with higher scores indicating greater severity
|
24 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Andrew N. Russman, D.O., Henry Ford Hospital
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HFHS-5284
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.